Maxigen Biotech Inc. (1783.TW)
TWD 43.3
(-0.12%)
TWD 43.3
(-0.12%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 131.88 Million TWD | -13.27% |
| 2022 | 152.06 Million TWD | 23.16% |
| 2021 | 123.46 Million TWD | 28.29% |
| 2020 | 96.24 Million TWD | -71.2% |
| 2019 | 334.16 Million TWD | 14.25% |
| 2018 | 292.47 Million TWD | -4.96% |
| 2017 | 307.72 Million TWD | -2.63% |
| 2016 | 316.03 Million TWD | -6.6% |
| 2015 | 338.38 Million TWD | 147.62% |
| 2014 | 136.65 Million TWD | 8.42% |
| 2013 | 126.04 Million TWD | 4.94% |
| 2012 | 120.1 Million TWD | 2.3% |
| 2011 | 117.4 Million TWD | 241.6% |
| 2010 | 34.36 Million TWD | 12.63% |
| 2009 | 30.51 Million TWD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 236.54 Million TWD | 73.29% |
| 2024 Q1 | 136.5 Million TWD | 3.5% |
| 2023 Q3 | 173.69 Million TWD | -11.25% |
| 2023 Q2 | 195.71 Million TWD | 31.81% |
| 2023 FY | 131.88 Million TWD | -13.27% |
| 2023 Q1 | 148.48 Million TWD | -2.36% |
| 2023 Q4 | 131.88 Million TWD | -24.07% |
| 2022 Q2 | 113.75 Million TWD | 4.5% |
| 2022 Q1 | 108.85 Million TWD | -11.83% |
| 2022 FY | 152.06 Million TWD | 23.16% |
| 2022 Q4 | 152.06 Million TWD | 18.78% |
| 2022 Q3 | 128.02 Million TWD | 12.54% |
| 2021 Q3 | 116.23 Million TWD | 2.89% |
| 2021 Q4 | 123.46 Million TWD | 6.22% |
| 2021 Q1 | 95.49 Million TWD | -0.78% |
| 2021 FY | 123.46 Million TWD | 28.29% |
| 2021 Q2 | 112.96 Million TWD | 18.3% |
| 2020 Q4 | 96.24 Million TWD | 6.04% |
| 2020 FY | 96.24 Million TWD | -71.2% |
| 2020 Q1 | 107.72 Million TWD | -67.76% |
| 2020 Q2 | 148 Million TWD | 37.39% |
| 2020 Q3 | 90.75 Million TWD | -38.68% |
| 2019 Q1 | 304.68 Million TWD | 4.17% |
| 2019 Q2 | 371.92 Million TWD | 22.07% |
| 2019 Q3 | 311.8 Million TWD | -16.16% |
| 2019 Q4 | 334.16 Million TWD | 7.17% |
| 2019 FY | 334.16 Million TWD | 14.25% |
| 2018 Q3 | 286.2 Million TWD | -7.41% |
| 2018 Q1 | 290.86 Million TWD | -5.48% |
| 2018 FY | 292.47 Million TWD | -4.96% |
| 2018 Q4 | 292.47 Million TWD | 2.19% |
| 2018 Q2 | 309.1 Million TWD | 6.27% |
| 2017 Q4 | 307.72 Million TWD | 3.32% |
| 2017 Q2 | 296.73 Million TWD | -1.48% |
| 2017 Q1 | 301.19 Million TWD | -4.7% |
| 2017 FY | 307.72 Million TWD | -2.63% |
| 2017 Q3 | 297.82 Million TWD | 0.37% |
| 2016 Q2 | 335.77 Million TWD | 0.94% |
| 2016 Q1 | 332.63 Million TWD | -1.7% |
| 2016 FY | 316.03 Million TWD | -6.6% |
| 2016 Q4 | 316.03 Million TWD | -1.55% |
| 2016 Q3 | 321.01 Million TWD | -4.39% |
| 2015 Q3 | 126.33 Million TWD | -11.11% |
| 2015 FY | 338.38 Million TWD | 147.62% |
| 2015 Q4 | 338.38 Million TWD | 167.85% |
| 2015 Q2 | 142.12 Million TWD | 14.02% |
| 2015 Q1 | 124.64 Million TWD | -8.78% |
| 2014 Q1 | 133.69 Million TWD | 6.07% |
| 2014 Q4 | 136.65 Million TWD | -0.12% |
| 2014 FY | 136.65 Million TWD | 8.42% |
| 2014 Q3 | 136.82 Million TWD | 5.44% |
| 2014 Q2 | 129.76 Million TWD | -2.94% |
| 2013 FY | 126.04 Million TWD | 4.94% |
| 2013 Q2 | 116.71 Million TWD | 0.0% |
| 2013 Q3 | 120.33 Million TWD | 3.1% |
| 2013 Q4 | 126.04 Million TWD | 4.74% |
| 2013 Q1 | - TWD | -100.0% |
| 2012 Q4 | 120.1 Million TWD | 0.0% |
| 2012 FY | 120.1 Million TWD | 2.3% |
| 2012 Q2 | 124.47 Million TWD | 0.0% |
| 2011 Q2 | 126.03 Million TWD | 0.0% |
| 2011 Q4 | 117.4 Million TWD | 0.0% |
| 2011 FY | 117.4 Million TWD | 241.6% |
| 2010 Q4 | 34.36 Million TWD | 0.0% |
| 2010 FY | 34.36 Million TWD | 12.63% |
| 2009 FY | 30.51 Million TWD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Nang Kuang Pharmaceutical Co., Ltd. | 1.47 Billion TWD | 91.083% |
| SciVision Biotech Inc. | 533.66 Million TWD | 75.287% |
| Bionime Corporation | 3.3 Billion TWD | 96.012% |
| Pegavision Corporation | 3.87 Billion TWD | 96.6% |
| Visco Vision Inc. | 1.74 Billion TWD | 92.427% |